Cancer Research

{
  "result": " In this research cycle, the Gonka Labs swarm advanced a deliberately rigorous, multi-pronged strategy to untangle how cholesterol handling and tissue-level inflammation may drive distinct subtypes of colorectal cancer. Rather than mining for loose correlations, the AI parallelized three precision pipelines: constructing tissue-specific genetic instruments for the LDLR cholesterol receptor and the inflammatory enzyme PTGS2 (COX-2); testing whether metabolic risk profiles alter their causal effects on microsatellite-stable (MSS) versus microsatellite-instable (MSI) tumors; and mining genome-wide CRISPR knockout screens to find subtype-specific genetic dependencies. The most significant development is not a finished biological claim, but the assembly of this convergent-evidence framework itself—one that demands human population genetics and cellular dependency data point in the same direction before any causal edge is accepted.\n\nTo understand the stakes, MSS and MSI colorectal cancers represent two fundamentally different biological paths. MSI tumors accumulate spelling errors across their DNA because their repair machinery is broken, often provoking an immune response; MSS tumors, which are more common, typically thrive through chromosomal instability and stromal inflammation. The swarm is asking whether LDLR—essentially a gatekeeper for cholesterol uptake—and PTGS2—a key driver of inflammatory signaling in immune cells and the surrounding tumor scaffold—truly cause one subtype to flourish over the other, or merely correlate with it. Because simple genetic associations are easily confounded, the AI is using Mendelian randomization, a technique that treats naturally inherited genetic variants as randomized trial assignments, but only after verifying through colocalization analysis that the same DNA variant appears to control both gene activity and disease risk.\n\nNo hardened causal relations were added to the knowledge base this cycle, and the swarm’s tally of confirmed causal links remains at zero. However, four hypotheses were updated and refined, suggesting the AI is actively pruning weaker models and sharpening the conditions under which evidence would be accepted. The swarm deliberately deprioritized off-target literature—including unrelated fields such as orthopedic surgery and heart failure monitoring—and set aside tangential targets such as PCSK9 and JAK1 to avoid diluting its signal. This restraint indicates that the current phase is foundational: building sufficiently strong, tissue-matched genetic instruments from liver, colon, macrophage, and fibroblast atlases before executing the final statistical contrasts.\n\nThe immediate open questions are whether the liver- and colon-specific genetic switches near LDLR share a single causal variant with the MSS/MSI risk signals detected in large multi-ancestry genome-wide association studies, and whether PTGS2 activity in macrophages and cancer-associated fibroblasts maps to the same genomic signals as CRC risk more convincingly than tumor-cell expression alone. On the cellular side, the swarm needs to determine if CRISPR knockout of PTGS2 is synthetically lethal—fatal only when combined with APC mutations or MSI-high instability—and whether LDLR loss differentially harms MSS versus MSI cells depending on their metabolic wiring. The next cycle will focus on executing these colocalization and dependency contrasts. While confidence in the overall framework is cautiously high, confidence in any specific biological claim remains appropriately low until these independent streams converge.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}